News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was âsignificantly improvedâ as compared to placeboâthe second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyoâs ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisionsâthe CDC and the FDAâs two primary review units.
THE LATEST
Topline Phase 3 results of survodutideâlicensed to Boehringer Ingelheim from Zealand Pharmaâare more comparable to Novo Nordiskâs Wegovy than to Eli Lillyâs Zepbound, William Blair analysts said on Tuesday.
Cancer cocktails pairing Modernaâs mRNA-4359 with Merckâs Keytruda and Marengoâs invikafusp alfa with Gilead Sciencesâ Trodelvy showed promising results, while a complex combination by Agenus and MiNK Therapeutics failed to elicit an overall response.
Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.
The FDA has renewed calls for Amgenâs Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results of the drugâs pivotal study in order to make it look effective.
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
Coultreon Biopharma is advancing assets that target salt-inducible kinases, proteins that drive inflammation and other immune-mediated conditions.
Fresh off a major clinical win, Revolution Medicines alleges that Erascaâs pancreatic cancer drug infringes on key patent protections and that the rival has âimproperly comparedâ the companiesâ assets publicly.
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.
Compass shares crash as âconfoundingâ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Sun Pharmaceutical is bringing Merck spinoff Organon into the fold, paying $11.75 billion in hopes of becoming a top global biosimilar player.